Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01873729 · ClinicalTrials.gov registry record · Phase 4
An Open-Label Study of Naltrexone in Adults With Attention Deficit Hyperactivity Disorder.
A Phase 4 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 3
- Enrollment target
NCT01873729: Completed Phase 4 study, sponsored by Massachusetts General Hospital.
NCT01873729 is a Phase 4 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 3 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01873729, a Phase 4 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 3 participants
- Enrollment target
Study Summary
The primary aim of this study is to assess whether naltrexone as a monotherapy is effective in treating Attention Deficit Hyperactivity Disorder (ADHD) in adults. Medications that increase dopamine are often effective in treating ADHD in adults. Since naltrexone is a kappa opioid receptor antagonist, it increases dopamine in the brain. We predict that naltrexone as a monotherapy will be effective for ADHD symptoms in adults with ADHD.
Interventions
- DRUG Naltrexone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2013-11 |
| Est. Completion | 2016-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01873729
The ClinicalTrials.gov registry entry for NCT01873729 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Naltrexone is the first listed.
NCT01873729 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01873729 about?
NCT01873729 is a clinical study titled "An Open-Label Study of Naltrexone in Adults With Attention Deficit Hyperactivity Disorder.". The primary aim of this study is to assess whether naltrexone as a monotherapy is effective in treating Attention Deficit Hyperactivity Disorder (ADHD) in adults. Medications that increase dopamine are often effective in treating ADHD in adults. Since naltrexone is a kappa opioid receptor antagonist...
What is the current status of trial NCT01873729?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 3 participants. The study started on 2013-11. Estimated completion is 2016-06.
What interventions are being tested in trial NCT01873729?
The interventions under investigation include: Naltrexone (DRUG).
Who is sponsoring clinical trial NCT01873729?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.